Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,615

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,615 results for “tumour”

Learn how ShareScore rates datasets ↗
zenodo32/100

Single cell data from Imaging Mass Cytometry of mouse lung tumours treated with KRAS-G12C and immune checkpoint inhibitors (Dataset 3)

Open the record for dataset details and reuse information.

opencc-by-4.0Jun 2024View details →
zenodo32/100

Transcriptome profiling associated with CARD11 overexpres-sion in Colorectal Cancer implicates a potential role for Tumour Immune Microenvironment and Cancer pathways modulation via NF-κB

<p>tables for CARD11</p>

opencc-by-4.0Jul 2024View details →
zenodo32/100

Systematic assessment of tumour purity and its clinical implications

<p>Supplemental data for the study:&nbsp;Systematic assessment of tumour purity and its clinical implications</p>

opencc-by-4.0Jul 2019View details →
zenodo32/100

Transcriptome profiling associated with CARD11 overexpres-sion in Colorectal Cancer implicates a potential role for Tumour Immune Microenvironment and Cancer pathways modulation via NF-κB

<p>Images for CARD11 study in IJMS</p>

opencc-by-4.0Jul 2024View details →
zenodo32/100

Source data sets_Figure 1, 2, 6_Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity

<p>Flow cytometry data files associated with Copland&nbsp;<em>et al., </em><strong><em><span>Salmonella&nbsp;</span></em></strong><strong><span>cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity.</span></strong></p> <p><span>Data associated to Figures 1, 2 and 6.&nbsp;<br></span></p>

opencc-by-4.0Sep 2024View details →
zenodo32/100

Exploration of Biomarkers for the Susceptibility, Early Detection and Treatment Response of Brain Tumours using Epidemiological Techniques

<p>The following resource is from Lily Andrews thesis entitled: Exploration of Biomarkers for the Susceptibility, Early Detection and Treatment Response of Brain Tumours using Epidemiological Techniques. This presents tables that were too large to place in the appendix of the thesis.</p>

opencc-by-4.0Sep 2024View details →
zenodo32/100

A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease

<p>***<strong>These data supersede the previous release. Please disregard data uploaded prior to October 30th as the metadata was incorrect - note the correct data in Supplementary Table 1</strong>***</p> <p>A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.&nbsp;</p> <p>GEO ID for bam files and CellRanger pipeline output (filtered and unfiltered):&nbsp;<strong>GSE282122</strong></p> <p>TAURUS_raw_counts_annotated_final.h5ad: This file is the pooled data across all cell types</p> <p>UMAP_combined_objects.txt.gz: This file has the corresponding UMAP for pooled data</p> <p>PC_combined_objects.txt.gz: This file has the corresponding PC for pooled data</p> <p>paired_sample_list.csv: This file has the paired samples used in analysis for baseline/longitudinal analysis. For baseline analyses, please use baseline samples &gt; 6.5 inflammation score to recapitulate the analyses in the paper.</p> <p>Other data to be uploaded to Zenodo include H&amp;E slides. Please access interactive MDV browser here.</p>

opencc-by-4.0Oct 2024View details →
dryad32/100

An innovative non-invasive technique for subcutaneous tumour measurements

<p>In oncological drug development, animal studies continue to play a central role in which the volume of subcutaneous tumours is monitored to assess the efficacy of new drugs. The tumour volume is estimated by taking the volume to be that of a regular spheroid with the same dimensions. However, this method is subjective, insufficiently traceable, and is subject to error in the accuracy of volume estimates as tumours are frequently irregular.</p> <p><span>This paper reviews the standard technique for tumour volume assessment, calliper measurements, by conducting a statistical review of a large dataset consisting of 2,500 tumour volume measurements from 1,600 mice by multiple operators across 6 mouse strains and 20 tumour models. Additionally, we explore the impact of six different tumour morphologies on volume estimation and the detection of treatment effects using a computational tumour growth model. Finally, we propose an alternative method to callipers for estimating volume – BioVolume<sup>TM</sup>, a 3D scanning technique. BioVolume simultaneously captures both stereo RGB (Red, Green and Blue) images from different light sources and infrared thermal images of the tumour in under a second. It then detects the tumour region automatically and estimates the tumour volume in under a minute. Furthermore, images can be processed in parallel within the cloud and so the time required to process multiple images is similar to that required for a single image. We present data of a pre-production unit test consisting of 297 scans from over 120 mice collected by four different operators.</span></p> <p><span>This work demonstrates that it is possible to record tumour measurements in a rapid minimally invasive, morphology-independent way, and with less human-bias compared to callipers, whilst also improving data traceability. Furthermore, the images collected by BioVolume may be useful, for example, as a source of biomarkers for animal welfare and secondary drug toxicity / efficacy.</span></p>

opencc-zeroOct 2019View details →
dryad32/100

Data from: Resource competition promotes tumour expansion in experimentally evolved cancer

Tumour progression involves a series of phenotypic changes to cancer cells, each of which presents therapeutic targets. Here, using techniques adapted from microbial experimental evolution, we investigate the evolution of tumour spreading - a precursor for metastasis and tissue invasion - in environments with varied resource supply. Evolutionary theory predicts that competition for resources within a population will select for individuals to move away from a natal site (i.e. disperse), facilitating the colonisation of unexploited resources and decreasing competition between kin. After approximately 100 generations in environments with low resource supply, we find that MCF7 breast cancer spheroids (small in vitro tumours) show increased spreading. Conversely, spreading slows compared to the ancestor where resource supply is high. Common garden experiments confirm that the evolutionary responses differ between selection lines; with lines evolved under low resource supply showing a plastic spreading phenotype. These differences in spreading behaviour between selection lines are heritable (stable across multiple generations), and show that the divergently evolved lines differ in their response to resource supply. It is possible that prolonged resource limitation itself causes a stable switch toward dispersal-like behaviour and an increased sensitivity to resource availability without the need for genetic change. Different clinical strategies may be needed depending on whether tumour progression is due to stable or plastic effects. This study highlights the effectiveness of experimental evolution approaches in cancer cell populations and demonstrates how simple model systems might enable us to observe and measure key selective drivers of clinically important traits.

opencc-zeroDec 2016View details →
zenodo32/100

pelvic bone tumour dataset

<p>pelvic bone tumour dataset used for deep learning for 2d segmentation and 2d classification of pelvic bone tumours types</p>

opencc-by-4.0Oct 2021View details →
zenodo32/100

Fig. 7 in Alkaloids isolated from Tropaeolum tuberosum with cytotoxic activity and apoptotic capacity in tumour cell lines

Fig. 7. Effects of compounds on the apoptosis of different tumoral cells. Untreated cells as negative reference, with Dimethylenastron (CTK8F1368), as positive reference compound at IC50 = 0.23 μM, with compound 1 at IC50 = 29.06 μM and compound 2 at IC50 = 1.33 μM, for 72 h and were stained with fluorochromes Rho123 (Rhodamine 123) and IP (Propidium Iodide) and evaluated by flow cytometry. p &lt;0.0001 (t Tukey, Two-way ANOVA).

opennotspecifiedSep 2020View details →
ClinicalTrials.gov32/100

A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours

ClinicalTrials.gov study NCT04889599. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Venous Thromboembolism in Primary Pancreatic Tumour Resection

ClinicalTrials.gov study NCT05964621. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1

ClinicalTrials.gov study NCT04523116. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Complications of Transurethral Resection of the Bladder Tumour

ClinicalTrials.gov study NCT03029663. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

ClinicalTrials.gov study NCT03555032. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

ClinicalTrials.gov study NCT02992912. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea

ClinicalTrials.gov study NCT01234168. IPD Sharing: Not stated. Countries: 8. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

ClinicalTrials.gov study NCT04273061. IPD Sharing: NO. Countries: 1. Publications: 39.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Effects of Dexmedetomidine During IRE Procedures for Solid Tumours

ClinicalTrials.gov study NCT02044224. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record